Want to see SDGR full AI Analyst Report?
SDGR Stock Chart & Stats
$19.99
-$0.16(-1.06%)
At close: 4:00 PM EDT
$19.99
-$0.16(-1.06%)
Day’s Range― - ―
52-Week Range$10.95 - $23.02
Previous CloseN/A
Volume981.72K
Average Volume (3M)1.09M
Market Cap
$1.50B
Enterprise Value$920.43
Total Cash (Recent Filing)$413.74M
Total Debt (Recent Filing)$107.98M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 11, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding65,641,430
10 Day Avg. Volume960,063
30 Day Avg. Volume1,090,272
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.61
Price to Sales (P/S)5.13
P/FCF Ratio105.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside0.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$240.32M
Bulls Say, Bears Say
Bulls Say
Recurring Customer AdoptionStrong ACV growth across quarterly, first-half and trailing periods indicates expanding customer adoption and recurring commercial traction. This supports the software platform’s ability to deepen usage and grow its contracted revenue base over the medium term.
Liquidity And Operating DisciplineA substantial liquidity position and lower operating expenses provide funding flexibility while the company scales its software and drug discovery activities. Quarterly profitability also suggests improving cost control, although sustained profitability remains to be demonstrated.
Platform And Product ExpansionNew products and strategic technology partnerships can broaden Schrödinger’s addressable customer base and increase platform usage. Bunsen, predictive toxicology and other tools may create additional licensing opportunities beyond the established molecular modeling suite.
Bears Say
Persistent Losses And Cash BurnDespite strong revenue growth and healthy gross margins, the company continues to lose money and consume cash. If operating expenses remain above gross profit, Schrödinger may need to use its liquidity to fund operations, limiting financial self-sufficiency.
Hosted Transition PressureThe shift toward hosted licensing should support a more modern delivery model, but it creates multi-period revenue recognition and margin pressure. These effects can obscure underlying demand and slow reported financial improvement during the transition.
Growth Moderation And Adoption RiskManagement’s outlook is more moderate than Q2’s ACV growth rate, while predictive toxicology and other products require lengthy customer validation. Delayed adoption could postpone revenue contribution and increase execution risk around the company’s expansion plans.
Schrodinger News
SDGR FAQ
What was Schrodinger’s price range in the past 12 months?
Schrodinger lowest stock price was $10.95 and its highest was $23.02 in the past 12 months.
What is Schrodinger’s market cap?
Schrodinger’s market cap is $1.50B.
When is Schrodinger’s upcoming earnings report date?
Schrodinger’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Schrodinger’s earnings last quarter?
Schrodinger released its earnings results on Aug 05, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.494.
Is Schrodinger overvalued?
According to Wall Street analysts Schrodinger’s price is currently Undervalued.
Does Schrodinger pay dividends?
Schrodinger does not currently pay dividends.
What is Schrodinger’s EPS estimate?
Schrodinger’s EPS estimate is -0.7.
How many shares outstanding does Schrodinger have?
Schrodinger has 65,641,430 shares outstanding.
What happened to Schrodinger’s price movement after its last earnings report?
Schrodinger reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 8.598%.
Which hedge fund is a major shareholder of Schrodinger?
Currently, no hedge funds are holding shares in SDGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Schrodinger Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (0.05% Upside)
$20.00 (0.05% Upside)
Blogger Sentiment
Neutral
SDGR Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 35.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Schrodinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Company Deck
SDGR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum driven by robust ACV growth, accelerating hosted adoption, the early launch and customer deployment of Bunsen, notable one-time collaboration milestones (e.g., $10M Ajax milestone) and a return to quarterly profitability with a solid cash position. Counterbalancing this optimism are near-term margin and revenue recognition pressures from the accelerated hosted licensing transition, a decline in contribution revenue tied to grant timing, and multi-quarter adoption timelines for new products like predictive toxicology. Guidance shows moderate full-year ACV growth (10%–15%), reflecting a more conservative outlook than Q2’s run-rate. Overall, positives around product innovation, customer expansion, and financial position outweigh the transitional challenges while leaving some execution and timing risks to monitor.View all SDGR earnings summariesSDGR Stock 12 Month Forecast
Average Price Target
$20.00
▲(0.05% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
17.42% Mutual Funds
37.03% Other Institutional Investors
15.34% Public Companies and
Individual Investors